Tao Li (Chair) , Fang Liu (Co-chair) , Zafiris Daskalakis (Discussant)
{"title":"UNCOVERING THE GENETIC AND BIOLOGICAL UNDERPINNINGS OF SCHIZOPHRENIA","authors":"Tao Li (Chair) , Fang Liu (Co-chair) , Zafiris Daskalakis (Discussant)","doi":"10.1016/j.euroneuro.2024.08.038","DOIUrl":null,"url":null,"abstract":"<div><div>This symposium will feature cutting-edge research that leverages diverse genomic approaches to elucidate the complex etiology of schizophrenia. The presentations will span large-scale genetic association studies, novel sequencing technologies, and investigations of the gut microbiome - all with the goal of advancing our fundamental understanding of this debilitating psychiatric disorder.</div><div>The symposium will begin with a report on the largest genome-wide association study (GWAS) of schizophrenia conducted in an Eastern Asian population to date. The speaker will present findings on newly identified risk loci that provide insights into the unique genetic architecture of schizophrenia in this understudied ancestral group. Next, researchers will share results from a study utilizing long-read sequencing technology to comprehensively catalog de novo mutations in schizophrenia parent-offspring trios. This high-resolution approach has uncovered rare, disruptive variants missed by short-read sequencing that may confer substantial risk for the disorder. The symposium will also feature an investigation of the gut microbiome and its potential role in schizophrenia pathogenesis. The speaker will discuss metagenomic analyses revealing distinct microbiota signatures associated with the disease state, suggesting gut-brain axis mechanisms worthy of further exploration. Finally, the symposium will conclude with functional experiments probing the biological impact of D2R-DISC1 complex on antipsychotic treatment. The speaker will share findings from a comprehensive investigation using both patient-derived samples and mouse models of schizophrenia. Through a combination of proteomic analyses, pharmacological manipulations, and advanced molecular techniques, the researchers have uncovered novel insights into how the D2R-DISC1 signaling axis contribute to treatment response in schizophrenia.</div><div>Collectively, this symposium will showcase innovative genomic and experimental approaches that are revolutionizing our understanding of schizophrenia's complex etiology. The findings presented will inspire new hypotheses and accelerate the translation of genetic discoveries into improved diagnostic tools and targeted therapeutic strategies.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"87 ","pages":"Page 13"},"PeriodicalIF":6.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924977X24002372","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This symposium will feature cutting-edge research that leverages diverse genomic approaches to elucidate the complex etiology of schizophrenia. The presentations will span large-scale genetic association studies, novel sequencing technologies, and investigations of the gut microbiome - all with the goal of advancing our fundamental understanding of this debilitating psychiatric disorder.
The symposium will begin with a report on the largest genome-wide association study (GWAS) of schizophrenia conducted in an Eastern Asian population to date. The speaker will present findings on newly identified risk loci that provide insights into the unique genetic architecture of schizophrenia in this understudied ancestral group. Next, researchers will share results from a study utilizing long-read sequencing technology to comprehensively catalog de novo mutations in schizophrenia parent-offspring trios. This high-resolution approach has uncovered rare, disruptive variants missed by short-read sequencing that may confer substantial risk for the disorder. The symposium will also feature an investigation of the gut microbiome and its potential role in schizophrenia pathogenesis. The speaker will discuss metagenomic analyses revealing distinct microbiota signatures associated with the disease state, suggesting gut-brain axis mechanisms worthy of further exploration. Finally, the symposium will conclude with functional experiments probing the biological impact of D2R-DISC1 complex on antipsychotic treatment. The speaker will share findings from a comprehensive investigation using both patient-derived samples and mouse models of schizophrenia. Through a combination of proteomic analyses, pharmacological manipulations, and advanced molecular techniques, the researchers have uncovered novel insights into how the D2R-DISC1 signaling axis contribute to treatment response in schizophrenia.
Collectively, this symposium will showcase innovative genomic and experimental approaches that are revolutionizing our understanding of schizophrenia's complex etiology. The findings presented will inspire new hypotheses and accelerate the translation of genetic discoveries into improved diagnostic tools and targeted therapeutic strategies.
期刊介绍:
European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.